← All trials
NCT07297264
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2022
- Primary completion
- Feb 21, 2023
- Completion date
- Mar 26, 2023
- First posted
- Dec 22, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kurdistan Board for Medical SpecialistLead sponsor
- Kurdistan Board for Medical SpecialistOfficial
- Kurdistan Board for Medical SpecialistSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.